SEC 13F Intelligence

Managers / Q2 2025 · view latest →

Crestline Management, L.P.

CIK 0001536054 · 201 MAIN STREET, SUITE 2100, FORT WORTH, TX, 76102 · 817.339.7483

Reported Value
$63M
Q2 2025
Positions
3
Filings on Record
31
2019–present window
Filed
Aug 14, 2025
original filing

Summary

Crestline Management, L.P. reported $63M in U.S.-listed holdings across 3 positions for Q2 2025.

The portfolio is heavily concentrated: DNLI alone accounts for 86.3% of reported value.

The book was largely unchanged from Q1 2025.

Portfolio Metrics

Turnover
+3.1%
vs prior filed quarter
Largest Position
+86.3%
Denali Therapeutics

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q1 ’19: $461MQ1 ’19Q2 ’19: $743MQ3 ’19: $621MQ4 ’19: $772MQ1 ’20: $347MQ1 ’20Q2 ’20: $546MQ3 ’20: $678MQ4 ’20: $943MQ1 ’21: $788MQ1 ’21Q2 ’21: $1.2BQ3 ’21: $1.1BQ4 ’21: $1.3BQ1 ’22: $834MQ1 ’22Q2 ’22: $766MQ3 ’22: $740MQ4 ’22: $682MQ1 ’23: $842MQ1 ’23Q2 ’23: $958MQ3 ’23: $858MQ4 ’23: $1.2BQ1 ’24: $1.1BQ1 ’24Q2 ’24: $1.3BQ3 ’24: $1.9BQ4 ’24: $3.0BQ1 ’25: $63MQ1 ’25Q2 ’25: $63MQ3 ’25: $58MQ4 ’25: $53MQ1 ’26: $46MQ1 ’26filingsflow.com

Portfolio Composition

By security type
Common Stock: 100.0%
  • Common Stock · 100.0% · $63M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2025 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
SANASANA BIOTECHNOLOGY INCTRIMMED−370.0K2.42M+$2M$7M
DNLIDENALI THERAPEUTICS INCTRIMMED−300.0K3.86M−$3M$54M
EGHT8X8 INC NEWHELD+0990.6K−$39,634$2M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2025

3 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1DNLIDENALI THERAPEUTICS INChistory →COM86.33%$54M3.86M
2SANASANA BIOTECHNOLOGY INChistory →COM10.56%$7M2.42M
3EGHT8X8 INC NEWhistory →COM3.10%$2M990.6K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$46M3May 15, 2026RESTATEMENTchanges · EDGAR ↗
Q4 2025$53M3Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$58M3Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$63M3Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$63M3May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$3.0B705Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$1.9B514Nov 13, 202413F-HRchanges · EDGAR ↗
Q2 2024$1.3B159Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$1.1B157May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$1.2B157Feb 12, 202413F-HRchanges · EDGAR ↗
Q3 2023$858M143Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$958M148Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$842M157May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$682M165Feb 13, 202313F-HRchanges · EDGAR ↗
Q3 2022$740M201Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$766M221Aug 12, 202213F-HRchanges · EDGAR ↗
Q1 2022$834M256May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$1.3B227Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$1.1B236Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$1.2B177Aug 13, 202113F-HRchanges · EDGAR ↗
Q1 2021$788M98May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$943M141Feb 12, 202113F-HRchanges · EDGAR ↗
Q3 2020$678M91Nov 13, 202013F-HRchanges · EDGAR ↗
Q2 2020$546M160Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$347M32May 13, 2020RESTATEMENTchanges · EDGAR ↗
Q4 2019$772M41Feb 12, 202013F-HRchanges · EDGAR ↗
Q3 2019$621M79Nov 13, 201913F-HRchanges · EDGAR ↗
Q2 2019$743M82Aug 13, 201913F-HRchanges · EDGAR ↗
Q1 2019$461M3May 15, 201913F-HRchanges · EDGAR ↗

Other Included Managers

This filing reports holdings on behalf of 1 additional manager.

  • SummitTX Capital, L.P.028-14917

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.